<DOC>
	<DOCNO>NCT00017368</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . Peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy follow peripheral stem cell transplantation treat child newly diagnose neuroblastoma .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Treating Children With Newly Diagnosed Neuroblastoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine toxicity feasibility high-dose thiotepa cyclophosphamide autologous peripheral blood stem cell ( PBSC ) transplantation sargramostim ( GM-CSF ) follow high-dose carboplatin , etoposide , melphalan second PBSC transplantation , GM-CSF , isotretinoin induction child newly diagnose high-risk neuroblastoma . - Determine role meta-iodobenzylguanidine ( MIBG ) scan assess response tandem transplantation minimal residual disease therapy patient . - Determine feasibility quantitative polymerase chain reaction neuroblastoma-specific ribonucleic acid specific stage treatment prognostic indicator outcome patient . - Determine immune recovery quantitation lymphocyte subset patient limited functional analysis completion regimen . OUTLINE : This multicenter study . Patients stratify accord peripheral blood stem cell ( PBSC ) selection ( select PBSCs v unselected PBSCs ) . ( Selected PBSC stratum close accrual 7/17/02 . ) - Induction/harvest : - Course 1 : Patients receive etoposide ( VP-16 ) IV 1 hour day 2-4 , cisplatin IV 6 hour ( begin VP-16 infusion ) day 1-5 , filgrastim ( G-CSF ) subcutaneously ( SC ) begin day 6 continue blood count recover . - Course 2 : Patients receive vincristine IV doxorubicin IV 15 minute day 1 , cyclophosphamide IV 6 hour day 1 2 , sargramostim ( GM-CSF ) SC begin day 3 continue PBSC harvest . Beginning completion course 2 blood count recover , autologous PBSC harvest . - Course 3 : Patients receive VP-16 IV 1 hour ifosfamide IV 1 hour day 1-5 G-CSF SC begin day 6 continue blood count recover . - Course 4 : Patients receive VP-16 IV 1 hour day 1-3 , carboplatin IV 2 hour ( begin VP-16 infusion ) day 1 2 , G-CSF SC begin day 4 continue blood count recover . - Course 5 : Patients receive treatment course 2 support G-CSF . Courses 1-5 last 3-4 week . Patients undergo resection primary tumor course 4 5 unless primary resection complete diagnosis ( recommend ) , primary site find , primary site unresectable . Patients complete course 1-5 proceed first conditioning/PBSC transplantation ( PBSCT ) absence disease progression unacceptable toxicity . - First conditioning/PBSCT : Patients receive high-dose thiotepa IV day -7 -5 cyclophosphamide IV 1 hour day -5 -2 . CD34+ PBSC reinfused day 0 . GM-CSF administer SC begin day 5 continue blood count recover . If blood count recover day 28 , unselected PBSC reinfused . In absence disease progression unacceptable toxicity , patient proceed second conditioning/PBSCT . - Second conditioning/PBSCT : Beginning within 6-8 week initiate first conditioning , patient receive high-dose carboplatin IV continuously etoposide phosphate IV continuously day -7 -4 melphalan IV day -7 -5 . PBSC GM-CSF administer first PBSCT . Beginning early day 28 second PBSCT , patient undergo local radiotherapy primary site site positive meta-iodobenzylguanidine scan induction twice day 7 day ( day 12 day twice daily dose possible ) . Beginning day 90 second PBSCT , patient receive oral isotretinoin twice day 2 week . Treatment repeat every 4 week 6 course absence disease progression unacceptable toxicity . Patients follow every 3 month 1 year , every 6 month 1 year , annually thereafter . PROJECTED ACCRUAL : A total 31-39 patient accrue study within 22 month .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose highrisk neuroblastoma Histologically proven AND/OR Bone marrow specimen show clumps tumor cell accompany elevated urinary catecholamine Age 130 : Must meet one follow INSS stag criterion : Stage IV regardless biologic factor Stage IIa/IIb MYCN oncogene amplification ( great 10 ) unfavorable pathology Stage III MYCN oncogene amplification ( great 10 ) unfavorable pathology Initially stage I , II , IVS , progress without interval chemotherapy Under age 1 : INSS stage III , IV , IVS MYCN amplification ( great 10 ) Must enter neuroblastoma biology study COGANBL00B1 within 2 week diagnosis entry study PATIENT CHARACTERISTICS : Age : 30 original diagnosis Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No 1 prior course chemotherapy intergroup low intermediaterisk neuroblastoma study prior determination MYCN status Shimada histology Endocrine therapy : Not specify Radiotherapy : Prior emergent radiotherapy sit function lifethreatening neuroblastoma allow Surgery : Not specify Other : No prior systemic therapy neuroblastoma</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>regional neuroblastoma</keyword>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>localize unresectable neuroblastoma</keyword>
	<keyword>stage 4S neuroblastoma</keyword>
</DOC>